The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of p53 mutation as a predictive biomarker for outcome to chemotherapy in ovarian cancer.
A. H. Calvert
No relevant relationships to disclose
J. C. Jackson
No relevant relationships to disclose
C. Hutton
No relevant relationships to disclose
A. M. Swart
No relevant relationships to disclose
W. Qian
No relevant relationships to disclose
C. Kwakye
No relevant relationships to disclose
R. Fossati
No relevant relationships to disclose
A. Lissoni
No relevant relationships to disclose
P. G. Harper
No relevant relationships to disclose
N. Colombo
No relevant relationships to disclose
R. J. Edmondson
No relevant relationships to disclose
J. Lunec
No relevant relationships to disclose